secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2026-09-29T11:03:49+00:00
Accession:  0001326190-26-000056
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4.1-flash:cloud@v2

Altimmune names Richard Menziuso VP, Global Controller and Principal Accounting Officer, effective Sept 29
--------------------------------------------------------------------------------

- Richard Menziuso, 51, appointed Vice President, Global Controller and Principal Accounting Officer effective September 29, 2026; CFO Gregory Weaver remains in his role.
- Menziuso was VP, Corporate Controller at Centessa Pharmaceuticals from 2021 until its 2026 acquisition by Eli Lilly; before that North America Controller at Thermo Fisher (2019-2021).
- Earlier roles: VP, Accounting and Controller at Axovant Gene Therapies (2017-2019) and finance positions at LifeCell, ConvaTec, Tyco, PricewaterhouseCoopers and Bristol-Myers Squibb.
- He brings 28 years of finance and accounting experience, including 12 in public accounting, and holds a B.B.A. from Pace University; he is a CPA and Chartered Global Management Accountant.
- Company will enter an indemnification agreement with Menziuso mirroring those for other executive officers; no family relationships or Item 404(a) related-party transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619026000056/0001326190-26-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619026000056/alt-20260924x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-26-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer